Allergy Therapeutics plc (AGY) Earns “Buy” Rating from FinnCap
FinnCap reaffirmed their buy rating on shares of Allergy Therapeutics plc (LON:AGY) in a research report released on Thursday morning. The brokerage currently has a GBX 43 ($0.53) price target on the stock.
Several other brokerages have also recently issued reports on AGY. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 60 ($0.74) price objective on shares of Allergy Therapeutics plc in a research note on Tuesday, February 14th. Panmure Gordon reaffirmed a buy rating and issued a GBX 53 ($0.65) price objective on shares of Allergy Therapeutics plc in a research note on Thursday, January 26th. Finally, Numis Securities Ltd reaffirmed a buy rating and issued a GBX 37 ($0.46) price objective on shares of Allergy Therapeutics plc in a research note on Thursday, January 19th.
Shares of Allergy Therapeutics plc (LON:AGY) opened at 27.00 on Thursday. Allergy Therapeutics plc has a 52-week low of GBX 17.25 and a 52-week high of GBX 29.00. The stock has a 50 day moving average of GBX 26.23 and a 200 day moving average of GBX 22.55. The firm’s market cap is GBX 159.07 million.
Your IP Address:
About Allergy Therapeutics plc
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.
Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.